Although AMY has been implicated in the pathogenesis of diabetes and obesity, leading to the clinical use of its pharmaceutical analogue, pramlintide, as an FDA-approved anti-diabetic drug lowering body weight and hyperglycemia [39], our findings in mice can only confirm CTR signaling role in glucose handling and moreover extend these observations to plasma lipid levels. The gene discussed is CALCR; the disease is obesity due to melanocortin 4 receptor deficiency.